Listed

Protalix BioTherapeutics, Inc.: Form 10-K for the period ended Dec 31, 2016

Filed with the SEC on Mar 16, 2017 and accepted by EDGAR at Mar 16, 2017, 16:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2016-01-01 to 2016-12-31$9.2mus-gaap:Revenues
Cost of revenue12 months2016-01-01 to 2016-12-31$8.4mus-gaap:CostOfRevenue
Gross profit12 months2016-01-01 to 2016-12-31$801.0kus-gaap:GrossProfit
Research and development12 months2016-01-01 to 2016-12-31$30.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2016-01-01 to 2016-12-31$9.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2016-01-01 to 2016-12-31−$33.2mus-gaap:OperatingIncomeLoss
Net income12 months2016-01-01 to 2016-12-31−$29.4mus-gaap:NetIncomeLoss
Diluted EPS12 months2016-01-01 to 2016-12-31−$0.29us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2016-01-01 to 2016-12-31−$32.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2016-01-01 to 2016-12-31$849.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-12-31$63.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-12-31$71.9mus-gaap:AssetsCurrent
Total assetsAt period end2016-12-31$82.2mus-gaap:Assets
Current liabilitiesAt period end2016-12-31$66.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-12-31$92.2mus-gaap:Liabilities
Shareholders' equityAt period end2016-12-31−$10.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-17-015083. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.